IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9969809 B1

PDFFull Text
Date of Patent:
May. 15, 2018

Filed:

Mar. 30, 2016

Therapeutic antibodies and their uses

Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Tracy Chia-Chien Kuo, San Mateo, CA (US);

Javier Fernando Chaparro Riggers, San Mateo, CA (US);

Wei Chen, Cupertino, CA (US);

Amy Shaw-Ru Chen, San Jose, CA (US);

Edward Derrick Pascua, Oakland, CA (US);

Thomas John Van Blarcom, Oakland, CA (US);

Leila Marie Boustany, Redwood City, CA (US);

Weihsien Ho, Belmont, CA (US);

Yik Andy Yeung, South San Francisco, CA (US);

Pavel Strop, San Mateo, CA (US);

Arvind Rajpal, San Francisco, CA (US);

Assignee:

PFIZER INC., New York, NY (US);

Attorney:

Jenny J. Yeh

Primary Examiner:

Laura B Goddard

Assistant Examiner:

Meera Natarajan

Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/454 (2006.01); A61K 31/704 (2006.01); A61K 47/48 (2006.01); A61K 31/69 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 31/454 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 47/48376 (2013.01); A61K 47/48561 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.

Find Patent Forward Citations

Loading…